Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV , ZAP-70, and MRD

Ekaterina Kim, Shih-Shih Chen, Mariela Sivina, Hyunsoo Hwang, Xuelin Huang, Alessandra Ferrajoli, Nitin Jain, William G. Wierda, Dominik Wodarz, Nicholas Chiorazzi, Jan A. Burger

Blood (2024) 144 (25): 2678–2681.

https://doi.org/10.1182/blood.2024025683

Published: 2024

Includes: Supplemental data

Journal Articles

Infiltration of Malignant B Cells Suppresses and Re-Organizes Lymph Node Fibroblasts in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Yu-Ju Chen, Nikhil Trepeta, Stella Fratti, Kelly Wong, Alan G. Ramsay, Shih-Shih Chen

Blood (2024) 144 (Supplement 1): 1853.

https://doi.org/10.1182/blood-2024-212227

Published: 2024

Journal Articles

Eradication of the CLECL1+ CLL Subset That Is Prone to Carrying Novel Genomic Mutations and Promoting a Pro-Tumor Microenvironment By a Series of New Monoclonal Antibodies Reactive with Distinct Target Epitopes

Shih-Shih Chen, Susan Buhl, Anita Kar Yun Ng, Laila Schipper, Bianca Cinquemani, Nikhil Trepeta, Martina Cardillo, Gonzalo Blanco, Kelly Wong, Yu-Ju Chen, Xiao J. Yan, Matthew Scharff, Nicholas Chiorazzi

Blood (2024) 144 (Supplement 1): 74.

https://doi.org/10.1182/blood-2024-200296

Published: 2024

Journal Articles

Integrin Signaling Pathway Is Crucial for the Recently Divided Fraction of CLL Cells and Facilitates Cell Migration in a Disease Progressive Manner

Xiao J. Yan, Florencia Palacios, Shih-Shih Chen, Wentian Li, Joanna M. Rhodes, Jacqueline C. Barrientos, Steven L Allen, Jonathan E. Kolitz, Kanti R Rai, Nicholas Chiorazzi

Blood (2022) 140 (Supplement 1): 4125–4126.

https://doi.org/10.1182/blood-2022-170042

Published: 2022

Journal Articles

CLECL1 + CLL Cells: A Key Subset That Drives CLL Survival and Proliferation and Shapes a Th2-Biased Tumor Microenvironment

Shih-Shih Chen, Xiao-Jie Yan, Martina Cardillo, Anita Ng, Andrew Shih, Gonzalo Blanco, Morgan King-Richards, Yu-Ju Chen, Yasmine Kieso, Joanna M. Rhodes, Kanti R Rai, Nicholas Chiorazzi

Blood (2022) 140 (Supplement 1): 1528–1529.

https://doi.org/10.1182/blood-2022-163353

Published: 2022

Journal Articles

Anti-CD70 Monoclonal Antibodies Show Efficacy in Preclinical Models for Chronic Lymphoblastic Leukemia

Shih-Shih Chen, Xiao-Jie Yan, Luc Van Rompaey, Piotr Zabrocki, Nicholas Chiorazzi

Blood (2022) 140 (Supplement 1): 1803–1804.

https://doi.org/10.1182/blood-2022-159016

Published: 2022

Journal Articles

Efficacy of Ibrutinib Monotherapy in Pre-Clinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue

Shih-Shih Chen, Jacqueline Barrientos, Xiao-Jie Yan, Uwe Wirtz, Edith Szafer-Glusman, Kanti R Rai, Nicholas Chiorazzi

Blood (2021) 138 (Supplement 1): 3708.

https://doi.org/10.1182/blood-2021-153685

Published: 2021

Journal Articles

CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib

Shih-Shih Chen, PhD, Constantine S. Tam, MBBS (Hons), MD, Alan G. Ramsay, BSc,MSc,PhD, Priyadarshini Ravichandran, Natalia C. Couto-Francisco, Michael Ibrahim, Gerardo Ferrer, PhD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, He Zhou, Jacqueline C Barrientos, MD, Kanti R Rai, MD, Nicholas Chiorazzi, MD

Blood (2019) 134 (Supplement_1): 477.

https://doi.org/10.1182/blood-2019-127255

Published: 2019

Journal Articles

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Blood (2019) 134 (6): 534–547.

https://doi.org/10.1182/blood.2018881029

Published: 2019

Includes: Supplemental data

Journal Articles

Ibrutinib Treatment Reduces Myeloid Derived Suppressor Cell Numbers and Function in Chronic Lymphocytic Leukemia

Gerardo Ferrer, PhD, Byeongho Jung, BS, Aslam Rukhsana, MD, Pui Yan Chiu, Andrea Nicola Mazzarello, PhD, Florenca Palacios, PhD, Shih-Shih Chen, PhD, Xiao J. Yan, MDPhD, Jacqueline C. Barrientos, MD MS, Jan A. Burger, MD PhD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, Kanti R Rai, MD, Barbara Sherry, PhD, Nicholas Chiorazzi, MD

Blood (2018) 132 (Supplement 1): 239.

https://doi.org/10.1182/blood-2018-99-114799

Published: 2018

Journal Articles

Dual Inhibition of PI3K-δ and PI3K-γ By Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Patient-Derived Xenograft Model

Shih-Shih Chen, PhD, Jeffery Lorne Kutok, MD PhD, Gerardo Ferrer, PhD, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, MSCR, Jacqueline C Barrientos, MD MS, David T. Weaver, PhD, Jonathan A Pachter, PhD, Kanti R Rai, MD, Nicholas Chiorazzi, MD

Blood (2018) 132 (Supplement 1): 4420.

https://doi.org/10.1182/blood-2018-99-109853

Published: 2018

Journal Articles

Serum IgM/Fcmr Interactions Inhibit BCR Signaling and Influence the Cinical Course of CLL

Stefania Gobessi, PhD, Luca Laurenti, MD, Fabiola Porro, MS, Claudio Martines, MS, Rosa Fazio, BS, Elena Xerxa, PhD, Idanna Innocenti, MD PhD, Antonella Zucchetto, Shih-Shih Chen, PhD, Xiao-Jie Yan, MD PhD, Nicholas Chiorazzi, MD, Valter Gattei, MD, Dimitar G Efremov, MD PhD

Blood (2018) 132 (Supplement 1): 4409.

https://doi.org/10.1182/blood-2018-99-118562

Published: 2018

Journal Articles

CLL Intraclonal Fractions Defined By Time Since Cell Birth/Division Promote a Leukemia-Supportive, Immune-Tolerant Microenvironment By Distinct Mechanisms

Shih-Shih Chen, PhD, Xiao J. Yan, MD PhD, Thomas M. Herndon, MD, Clare C. Sun, MD, Priyadarshini Ravichandran, Michael Ibrahim, Barbara Sherry, PhD, Adrian Wiestner, MD, Kanti R Rai, MD, Nicholas Chiorazzi, MD

Blood (2018) 132 (Supplement 1): 1836.

https://doi.org/10.1182/blood-2018-99-119843

Published: 2018

Journal Articles

Ibrutinib Disrupts IL-4R - IL-4 Axis By Inhibiting IL-4R Signaling and Reversing Th2/Th1 Polarization through Diminished CLECL1 in CLL B Cells

Shih-Shih Chen, PhD, Priyadarshini Ravichandran, Gerardo Ferrer, PhD, Andrea Nicola Mazzarello, PhD, Florencia Palacios, PhD, Michael Ibrahim, Yasmine Kieso, Jacqueline C. Barrientos, MD, Edward Clark, PhD, Barbara Sherry, PhD, Jan A. Burger, MD PhD, Kanti Rai, MD, Nicholas Chiorazzi, MD

Blood (2017) 130 (Supplement 1): 387.

https://doi.org/10.1182/blood.V130.Suppl_1.387.387

Published: 2017

Journal Articles

IgM and IgD Differential CLL BCRs Organization and Interaction with Co-Receptors before and during Ibrutinib Therapy

Andrea Nicola Mazzarello, PhD, Marcus Dühren-von Minden, PhD, Palash Chandra Maity, PhD, Gentner Eva, PhD, Stefano Vergani, PhD, Gerardo Ferrer, PhD, Davide Bagnara, PhD, Shih-Shih Chen, PhD, Sophia Yancopoulos, Xiao J. Yan, MDPhD, Jacqueline C. Barrientos, MD, Kanti Rai, MD, Hassan Jumaa, PhD, Nicholas Chiorazzi, MD

Blood (2017) 130 (Supplement 1): 1716.

https://doi.org/10.1182/blood.V130.Suppl_1.1716.1716

Published: 2017

Journal Articles

In CLL, Myeloid-Derived Suppressor Cells and Their Monocytic and Granulocytic Varieties Differ in T-Cell Subset Association and Polarization Induction

Gerardo Ferrer, PhD, Brendan Franca, Pui Yan Chiu, MSc, Stefano Vergani, MS, Andrea Nicola Mazzarello, PhD, Florencia Palacios, PhD, Davide Bagnara, PhD, Shih-Shih Chen, PhD, Sophia Yancopoulos, PhD, Yun Liu, MS, Aliki Xochelli, MD PhD, Xiao-Jie Yan, MD PhD, Jacqueline C. Barrientos, MD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, Kostas Stamatopoulos, MD PhD, Kanti R. Rai, MD, Barbara Sherry, PhD, Nicholas Chiorazzi, MD

Blood (2016) 128 (22): 4350.

https://doi.org/10.1182/blood.V128.22.4350.4350

Published: 2016

Journal Articles

In Vivo modeling of Resistance to PI3Kδ Inhibitor Treatment Using EµTCL1-Tg Tumor Transfer Model

Annika Scheffold, Billy Michael Chelliah Jebaraj, Eugen Tausch, Anella Yahiaoui, Anna Dolnik, PhD, Tamara Jacqueline Blaette, M.sc., Lars Bullinger, MD, Christof Schneider, MD, Daniel Mertens, PhD, Veerendra Munugalavadla, Shih-Shih Chen, PhD, Nicholas Chiorazzi, MD, Stacey Tannheimer, Hartmut Döhner, MD, Stephan Stilgenbauer

Blood (2016) 128 (22): 190.

https://doi.org/10.1182/blood.V128.22.190.190

Published: 2016

Journal Articles

In Vivo Evidence of in Situ Cell Death Preferentially Occurring in CLL Patients with Minimal Lymphocytosis By the Diminished BCL2 and Loss of T Cell Support after Ibrutinib Treatment

Shih-Shih Chen, PhD, Steven Ham, Priyadarshini Ravichandran, Ileana D'Aloisio, Emily Kate Butera, Romi Lyallpuri, Yasmine Kieso, Jacqueline C. Barrientos, MD, Kanti R Rai, Jan Burger, MD PhD, Nicholas Chiorazzi, MD

Blood (2016) 128 (22): 5586.

https://doi.org/10.1182/blood.V128.22.5586.5586

Published: 2016

Journal Articles

Comparative Density Analyses of B Cell Receptor-Complex Components (Membrane IgM, Membrane IgD, and Stimulatory/Inhibitory Co-Receptors) on Intraclonal Subpopulations of CLL B Cells, before and during Ibrutinib Therapy

Andrea Nicola Mazzarello, PhD, Stefano Vergani, MS, Gerardo Ferrer, PhD, Yun Liu, MS, Shih-Shih Chen, PhD, Sophia Yancopoulos, PhD, Xiao-Jie Yan, MD PhD, Jacqueline C. Barrientos, MD, Kanti R. Rai, MD, Nicholas Chiorazzi, MD

Blood (2016) 128 (22): 4356.

https://doi.org/10.1182/blood.V128.22.4356.4356

Published: 2016

Journal Articles

Dual Inhibition of PI3K-Delta and Gamma By Duvelisib (IPI-145) Impairs CLL B- and T-Cell Migration, Survival and Proliferation in a Murine Xenograft Model Using Primary Chronic Lymphocytic Leukemia Cells

Shih-Shih Chen, PhD, Steven Ham, Kanti R. Rai, MD, Karen McGovern, PhD, Jeffery L. Kutok, MD PhD, Nicholas Chiorazzi, MD

Blood (2015) 126 (23): 1753.

https://doi.org/10.1182/blood.V126.23.1753.1753

Published: 2015

NARROW

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV , ZAP-70, and MRD

Infiltration of Malignant B Cells Suppresses and Re-Organizes Lymph Node Fibroblasts in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Eradication of the CLECL1+ CLL Subset That Is Prone to Carrying Novel Genomic Mutations and Promoting a Pro-Tumor Microenvironment By a Series of New Monoclonal Antibodies Reactive with Distinct Target Epitopes

Integrin Signaling Pathway Is Crucial for the Recently Divided Fraction of CLL Cells and Facilitates Cell Migration in a Disease Progressive Manner

CLECL1 + CLL Cells: A Key Subset That Drives CLL Survival and Proliferation and Shapes a Th2-Biased Tumor Microenvironment

Anti-CD70 Monoclonal Antibodies Show Efficacy in Preclinical Models for Chronic Lymphoblastic Leukemia

Efficacy of Ibrutinib Monotherapy in Pre-Clinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue

CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Ibrutinib Treatment Reduces Myeloid Derived Suppressor Cell Numbers and Function in Chronic Lymphocytic Leukemia

Dual Inhibition of PI3K-δ and PI3K-γ By Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Patient-Derived Xenograft Model

Serum IgM/Fcmr Interactions Inhibit BCR Signaling and Influence the Cinical Course of CLL

CLL Intraclonal Fractions Defined By Time Since Cell Birth/Division Promote a Leukemia-Supportive, Immune-Tolerant Microenvironment By Distinct Mechanisms

Ibrutinib Disrupts IL-4R - IL-4 Axis By Inhibiting IL-4R Signaling and Reversing Th2/Th1 Polarization through Diminished CLECL1 in CLL B Cells

IgM and IgD Differential CLL BCRs Organization and Interaction with Co-Receptors before and during Ibrutinib Therapy

In CLL, Myeloid-Derived Suppressor Cells and Their Monocytic and Granulocytic Varieties Differ in T-Cell Subset Association and Polarization Induction

In Vivo modeling of Resistance to PI3Kδ Inhibitor Treatment Using EµTCL1-Tg Tumor Transfer Model

In Vivo Evidence of in Situ Cell Death Preferentially Occurring in CLL Patients with Minimal Lymphocytosis By the Diminished BCL2 and Loss of T Cell Support after Ibrutinib Treatment

Comparative Density Analyses of B Cell Receptor-Complex Components (Membrane IgM, Membrane IgD, and Stimulatory/Inhibitory Co-Receptors) on Intraclonal Subpopulations of CLL B Cells, before and during Ibrutinib Therapy

Dual Inhibition of PI3K-Delta and Gamma By Duvelisib (IPI-145) Impairs CLL B- and T-Cell Migration, Survival and Proliferation in a Murine Xenograft Model Using Primary Chronic Lymphocytic Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only